![As Biosimilar GCSF Looms Over U.S. Market, Big Players Line Up for Emerging Competition](https://cdn.cancerletter.com/media/2015/09/24001012/41-33-cola-beer-juice-biosimilar-cancer-drug.jpg)
![As Biosimilar GCSF Looms Over U.S. Market, Big Players Line Up for Emerging Competition](https://cdn.cancerletter.com/media/2015/09/24001012/41-33-cola-beer-juice-biosimilar-cancer-drug.jpg)
Cover Story
In the next few weeks, FDA will announce its decision on Novartis's Zarxio, a granulocyte-colony stimulating factor biosimilar to Amgen's Neupogen.
In Brief
Funding Opportunities
Drugs & Targets
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch